Shots:

• Immunic has exercised its exclusive option to license a group of compounds for Daiichi’s IMU-856. Daiichi to receive up front- certain future development- approval & sales milestone payments plus royalties on IMU-856. Immunic to get exclusive commercialization rights for IMU-856 in all countries- including the US- EU- and Japan
• Additionally- the option includes patent exclusivity filled by Daiichi for IMU-856’s composition of matter. In Nov- 2018 Daiichi signed an exclusive WW option and license agreement with Immunic for IMU-856
• IMU-856 is an orally administered modulator that restores the intestinal barrier function developed originally by Daiichi and will be evaluated in P-I for patients suffering from gastrointestinal diseases in H1’20

Click here to read full press release/ article | Ref: Immunic | Image: Behance